On Day 2 of the Clinical Trials Technology Congress 2026, the opening keynote explored how technology, real-time data and AI are transforming clinical development; enabling organisations to deliver smarter, more efficient clinical trials at scale.
Moderator & Speakers
Nicholas Lakin, Executive Managing Director, Syneos Health Consulting
Astrid Scherer, Head of Product Development and Process Excellence Clinical Development (VP), Bayer Pharmaceuticals
Rebecca Jackson, Associate Director, Global Development Systems, Johnson & Johnson
Raja Shankar, Vice President, Machine Learning, AI & Technology Solutions, IQVIA
To watch the talks and discussion please register below.
What does it take to deliver truly patient-centric clinical trials at scale?
In this CTTC session, our speakers explored how data, digital technologies and AI are helping organisations improve trial design, enhance the patient experience and overcome longstanding operational challenges.
Moderator & Speakers
Adama Ibrahim, former VP, R&ED Digital Transformation, Novo Nordisk
Sid Jain, SVP Clinical Development & Data Science , Recursion
Tom Willgoss, Therapeutic Area Lead – Immunology, Digital Endpoints and Patient-Centered Solutions, Roche
Pamela Tenaerts, Chief Medical Officer, Medable
To watch the discussion please register below.
In this opening keynote session from CTTC, leaders shared their perspectives on digital transformation, collaboration and the strategies needed to build smarter, faster clinical trials in a rapidly evolving landscape.
Moderator & Speakers
Adama Ibrahim, former VP, R&ED Digital Transformation, Novo Nordisk
Johannes Streffer, SVP Global Clinical Development, Lundbeck
Valdemar Borum Svarrer, Vice President, Head of Strategic & Digital Development, Data Science, Development, Novo Nordisk
Jenn Embury, Director Clinical and Regulatory Strategic Services, Astrix
To watch the session please register below.
This Digital Dialogue examined the current state of DHT use in clinical trials, with a focus on addressing the practical, regulatory, and scientific barriers limiting broader uptake. We were joined by five leaders in the Clinical space who highlighted the role of digital health technologies (DHTs), with particular emphasis on cross-sector collaborations driving real-world clinical trial impact.
Speakers
Jarjieh Fang, Director, HVE, Patient-Centered Outcomes Assessment, Pfizer
Jay Trudeau, Senior Director, Eli Lilly & Co
Marie McCarthy, Digital Endpoint Lead Director, Novartis
Farrell Healion, Founder and Principal Consultant, OptiTrial
Scottie Kern, Executive Director, eCOA Consortium, C-Path
In our Digital Dialogue, we explored how digital innovation is reshaping the clinical trials landscape, with a focus on enabling more inclusive, efficient, and patient-centred approaches.We were delighted to be joined by Matthew Bonam and Elaine Harrop for an engaging conversation on how digital innovation is transforming the way clinical trials are designed and delivered.
Speakers & Presentations
Overview of Evolving Clinical Trials Landscape and the Transformative Role of New and Emerging Technologies – Matthew Bonam, VP Digital Health Strategy, Evinova
Case Study: Reimagining Clinical Trials Operations in the Digital Era – Elaine Harrop, VP Clinical Operations, Respiratory & Immunology at AstraZeneca
To watch the discussion please fill out the form below.
